Boehringer Ingelheim and IBM team up to make antibodies with generative AI
Boehringer Ingelheim is the latest drugmaker turning to generative AI for help in making medicines. On Tuesday, the German pharma giant announced a partnership with IBM to create antibodies using the computer company’s artificial intelligence technology.
The companies, each among the oldest in their respective industries, are not merely jumping aboard the latest trend. Boehringer told Endpoints News that the partnership was years in the making. It sees using AI for drug design as a long-term investment, and not necessarily one that will flood its pipeline with drugs anytime soon.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.